The FDA just cleared Keytruda plus Padcev for muscle-invasive bladder cancer with no cisplatin requirement, filling a gap that left nearly half of patients without effective perioperative therapy. The clinical data is striking: 57% of patients had zero detectable cancer at surgery.
For decades, if you had muscle-invasive bladder cancer and needed surgery, your doctor had one playbook: cisplatin-based chemotherapy before the operation, then hope for the best. The problem? Roughly 30 to 50 percent of patients can't even tolerate cisplatin. And among those who can, many never receive it. The "gold standard" was more like a gold-plated standard that half the population couldn't afford to use.
On July 10, the FDA ripped up that playbook.
The agency approved Keytruda (pembrolizumab) combined with Padcev (enfortumab vedotin) as a perioperative treatment for adults with muscle-invasive bladder cancer (MIBC). That means before and after surgery, regardless of whether a patient can handle cisplatin.
This isn't just a new option. It's a potential new default.
The Biggest Shift in Bladder Cancer in a Generation
Let's set the scene. Muscle-invasive bladder cancer is exactly what it sounds like: cancer that has grown into the muscular wall of the bladder. The standard treatment involves removing the entire bladder (radical cystectomy) along with surrounding lymph nodes. To improve the odds, guidelines recommend cisplatin-based chemotherapy before surgery (neoadjuvant therapy) to shrink the tumor and kill stray cancer cells.
That approach has level-one evidence behind it. It works. But "works" comes with a giant asterisk.
Cisplatin is brutal on the kidneys. Patients need adequate kidney function, decent overall fitness, and no serious heart or nerve problems to qualify. Studies consistently show that a huge chunk of MIBC patients simply don't meet those criteria. For them, the standard of care was essentially: skip chemo, go straight to surgery, cross your fingers.
Even among patients eligible for cisplatin, uptake has been stubbornly low. One review put it bluntly: "the majority of contemporary patients with muscle-invasive disease do not receive this treatment," despite clear evidence it helps. Imagine knowing there's a life jacket on the boat and most passengers still aren't wearing one. That's the state of MIBC care.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This approval changes the math entirely.
What the Data Actually Showed
The approval is based on the Phase 3 KEYNOTE-905/EV-303 trial, which tested the Keytruda-plus-Padcev combination against surgery alone. The results were striking across every major endpoint.
Patients receiving the combo saw roughly a 60% reduction in the risk of their cancer coming back or getting worse (event-free survival). They also saw approximately a 50% reduction in the risk of death (overall survival). Those are massive numbers in oncology, where shaving 15 to 20 percent off a hazard ratio can get people excited.
But the stat that really turns heads is the pathologic complete response rate. That measures how many patients had zero detectable cancer left when surgeons actually removed the bladder and examined the tissue under a microscope. With the combo, 57% of patients achieved a complete response, compared to just 9% with surgery alone.
Think about that for a second. More than half the patients on the combo had no visible cancer left at the time of surgery. In the surgery-only group, fewer than one in ten could say the same.
Median event-free survival and overall survival in the combination arm hadn't even been reached at the time of analysis. In the surgery-only arm, median event-free survival was 15.7 months.
How the Treatment Actually Works
The regimen is a carefully choreographed sequence, not just "take two drugs and call me in the morning."
Before surgery (neoadjuvant phase): Patients receive three cycles over nine weeks. Each cycle includes Padcev on days one and eight, plus Keytruda on day one. On days when both drugs are given, Padcev goes first.
After surgery (adjuvant combination phase): The duo continues for six more cycles over 18 weeks.
Extended maintenance: After finishing the combination, patients can continue Keytruda alone for up to 42 total weeks of post-surgery treatment.
Padcev is an antibody-drug conjugate (think of it as a guided missile that delivers chemotherapy directly to cancer cells expressing a specific protein called Nectin-4). Keytruda is a checkpoint inhibitor that essentially takes the brakes off the immune system so it can attack cancer. Together, they hit the tumor from two completely different angles.
The FDA also cleared the option to use Keytruda Qlex, a subcutaneous formulation of pembrolizumab combined with berahyaluronidase alfa, instead of IV Keytruda. Same drug, different delivery method; it was first approved in September 2025 and gives patients (and infusion centers) a faster alternative to the traditional IV drip.
From Metastatic to Curable: The Combo's Rapid Climb
What makes this approval especially notable is the speed at which this combination has moved through the regulatory system. Consider the timeline:
February 2020: The FDA granted breakthrough therapy designation for the combo in advanced bladder cancer.
April 2023: Accelerated approval arrived for first-line metastatic bladder cancer in patients who couldn't tolerate cisplatin.
December 2023: Full approval followed for all first-line metastatic patients, based on blockbuster EV-302 trial data showing a median overall survival of 31.5 months versus 16.1 months with chemo.
November 2025: The combo moved into earlier-stage disease, winning approval for perioperative MIBC in cisplatin-ineligible patients.
July 2026: The cisplatin restriction disappeared entirely, opening the door to all adult MIBC patients.
That's a journey from "last resort in advanced cancer" to "standard perioperative therapy for potentially curable disease" in just over three years. In pharma terms, that's practically warp speed.
Follow the Money
The financial implications here are enormous, and they touch two of the biggest companies in pharma.
Merck owns Keytruda, which generated $8.03 billion in Q1 2026 alone (up 8% year over year). Merck needs new indications to sustain growth as patent cliffs loom. Bladder cancer, especially in a curative-intent setting where patients take the drug for nearly a year, is exactly the kind of high-value expansion that extends Keytruda's runway.
Pfizer inherited Padcev through its $43 billion acquisition of Seagen. The drug brought in $591 million in Q1 2026, up 39% year over year, and is on pace to be one of the crown jewels of the Seagen portfolio. Analysts at Evercore ISI have projected Padcev could hit $7 billion in peak annual sales globally, with $2.5 billion coming from first-line bladder cancer alone in the U.S.
Astellas, which co-commercializes Padcev with Pfizer in the U.S., recently raised its peak sales forecast for the drug from $2.7 billion to $3.4 billion by 2033.
Analysts have described the overall Keytruda-Padcev bladder cancer franchise as a potential $5 billion-plus peak revenue opportunity. This MIBC expansion is a big reason why. Perioperative use means longer treatment courses than metastatic settings, and the removal of the cisplatin eligibility restriction roughly doubles the addressable patient population overnight.
William Blair analysts have called the bladder cancer franchise a "commercial inflection point."
Why This Matters Beyond Wall Street
It's easy to get lost in the revenue projections and forget what's actually happening at the patient level. So let's zoom back out.
Bladder cancer is the sixth most common cancer in the United States. MIBC represents the most dangerous non-metastatic form, and until now, a significant portion of these patients had no proven systemic therapy to pair with surgery. They went under the knife with less protection than their cisplatin-eligible neighbors.
This approval doesn't just add a line to a prescribing label. It fills a gap that's existed for years, where guidelines essentially said "if you can't do cisplatin, we don't have much for you." Now there's a regimen with survival data, complete response rates north of 50%, and no cisplatin requirement.
The competitive landscape matters too. The EAU (European urology guidelines) recently recommended perioperative chemo-immunotherapy with cisplatin/gemcitabine plus durvalumab for eligible patients. But that regimen still requires cisplatin fitness. The Keytruda-Padcev combo sidesteps that limitation entirely, which could make it the preferred choice for oncologists who want one protocol that works across their entire MIBC patient population.
The Bottom Line
The FDA just gave bladder cancer patients something they haven't had before: a perioperative immunotherapy combination that doesn't care whether you can handle cisplatin. The clinical data is compelling (57% complete response rate, 60% reduction in recurrence risk, 50% reduction in death risk), the commercial opportunity is massive, and the unmet need was real.
For Merck and Pfizer, this is another chapter in what analysts are calling one of oncology's most important partnerships. For patients with muscle-invasive bladder cancer, it might be the chapter that matters most.
Clinical & Regulatory
5 min read
The FDA Just Overruled Its Own Experts on Moderna's Flu Shot
The FDA's vaccine advisory panel voted 9-0 that Moderna's mRNA flu shot was safe and effective. Then the agency rejected it anyway, on trial design grounds that blindsided the industry. The fallout could reshape how vaccine makers think about U.S. development for years.
